Join the Osteoporosis group to help and get support from people like you.
Osteoporosis News (Page 2)
Related terms: Bone Thinning
Researchers Discover New Hormone That Builds Strong Bones
WEDNESDAY, July 10, 2024 – A newly discovered hormone could help fight osteoporosis and quickly heal broken bones, researchers say. The research team identified Maternal Brain Hormone while trying...
USPSTF Recommends Osteoporosis Screening for Women Aged 65 Years and Older
TUESDAY, June 11, 2024 – The U.S. Preventive Services Task Force (USPSTF) recommends screening for osteoporosis for women aged 65 years and older and for postmenopausal women younger than 65 years...
FDA Approves Jubbonti (denosumab-bddz), an Interchangeable Biosimilar to Prolia
Basel, March 5, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) approved Jubbonti, (denosumab-bbdz), an i...
Radius Health’s Tymlos (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
Cambridge, Mass., December 20, 2022 – Radius Health, Inc. (“Radius” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Tymlos® (abaloparatide), a parathy...
FDA Approves Bonsity (teriparatide injection) to Treat Osteoporosis
SAN DIEGO, October 7, 2019 — Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA) has approved the new drug application (“NDA”) for Bonsity (PF708) submi...
FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture
April 9, 2019 – The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are...
FDA Approves Prolia (denosumab) for Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia (denosumab) for the treatment...
FDA Approves Tymlos (abaloparatide) for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
WALTHAM, Mass., April 28, 2017 (GLOBE NEWSWIRE) – Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing innovative...
Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle
Miami, FL and New York, NY, – September 24, 2014 – Noven Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication with a new dose of...
FDA Approves Binosto, First and Only Effervescent Osteoporosis Treatment in a Buffered Solution
FREIENBACH, Switzerland, March 14, 2012 /PRNewswire/ – EffRx Pharmaceuticals SA today announced that the U.S. Food and Drug Administration (FDA) has approved Binosto (alendronate sodium)...
Warner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel
ARDEE, Ireland, October 11, 2010 /PRNewswire-FirstCall/ – Warner Chilcott plc today announced that the United States Food and Drug Administration (FDA) has approved its next generation Actonel...
FDA Approves Amgen's Prolia (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture
THOUSAND OAKS, Calif., June 1, 2010 /PRNewswire via COMTEX/ --Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia (denosumab) for the treatment of...